Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.

Cancer immunology research - 1 Nov 2016

Shah Shalin, Ward James E, Bao Riyue, Hall Curtis R, Brockstein Bruce E, Luke Jason J

Abstract excerpt

Anti-Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti-PD-1 nor the incidence of an immunoresponsive tumor microenvironment has been described for GCTs. A patient initially diagnosed with melanoma via fine needle aspiration was treated with one dose of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Fetoproteins
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Immunotherapy

Share to Neoplasms, Germ Cell and Embryonal

Share to Programmed Cell Death 1 Receptor

Share to Testicular Neoplasms

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 27638840
DOI: 10.1158/2326-6066.CIR-16-0087
PMCID: PMC5104156

Genes

AFP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.PMID 27638840Read ↗

Frequent PD-L1 expression in testicular germ cell tumorsSemantic proximity Read ↗

Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targetsSemantic proximity Read ↗

T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsetsSemantic proximity Read ↗

Unwrapping the immunological alterations in testicular germ cell tumors: From immune homeostasis to malignancy and emerging immunotherapiesSemantic proximity Read ↗

Dysgerminoma germ cell tumors exhibit high expression of PD-L1 and are associated with high levels of tumor-infiltrating lymphocytes and a good patient prognosisSemantic proximity Read ↗

Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumorsSemantic proximity Read ↗

Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment developmentSemantic proximity Read ↗

Massive expression of germ cell specific genes is a hallmark of cancer and a potential target for novel treatment developmentSemantic proximity Read ↗

Testicular germ cell tumorsSemantic proximity Read ↗

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitorsSemantic proximity Read ↗

Evaluation of melanoma antigen (MAGE) gene expression in human cancers using The Cancer Genome Atlas.Semantic proximity Read ↗

French AFU Cancer Committee Guidelines – Update 2024–2026: Testicular germ cell cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.